ストックスクリーナーアプリを入手
11.62
0.61%
0.07
アフターアワーズ：
11.63
0.01
+0.09%
前日終値:
$11.55
開ける：
$11.54
24時間の取引高:
216.07K
Relative Volume:
0.94
時価総額：
$230.39M
収益：
$33.18M
当期純損益:
$-85.15M
株価収益率:
-3.8664
EPS:
-3.0054
ネットキャッシュフロー:
$-58.25M
1週間 パフォーマンス:
+3.84%
1か月 パフォーマンス:
-0.51%
6か月 パフォーマンス:
+2.47%
1年 パフォーマンス:
-26.46%
1日の値動き範囲:
$11.29
$11.70
1週間の範囲:
$10.97
$12.05
52週間の値動き範囲:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.62 | 229.00M | 33.18M | -85.15M | -58.25M | -3.0054 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
Live Keros Therapeutics, Inc. (KROS) Technical Analysis - Traders Union
Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with 74.59% Upside Potential - DirectorsTalk Interviews
Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026) - Stock Titan
(KROS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bank of New York Mellon Corp Takes $1.11 Million Position in Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics May Offer Up To $350 Million Of SecuritiesSEC Filing - TradingView
Share Buyback Program Approved by Keros Therapeutics (NASDAQ:KROS) Board of Directors - marketbeat.com
Keros Therapeutics (NASDAQ: KROS) Launches $5M Stock Buyback Program Following $20M Milestone from Takeda - Kalkine Media
Keros Therapeutics Announces Share Repurchase Authorization Program - TipRanks
Keros Therapeutics Announces $5 Million Share Repurchase Authorization - The Manila Times
Keros approves $5M buyback after $20M Takeda milestone; cash runway into H2 2028 - TradingView
Keros Therapeutics announces $5M share repurchase program after Takeda payment - TipRanks
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Keros Therapeutics, Inc. authorizes a Buyback Plan. - marketscreener.com
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell" - marketbeat.com
Keros Therapeutics (NASDAQ:KROS): Is Its Pipeline Worth the Risk? - Kalkine Media
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com - Investing.com South Africa
Keros Therapeutics director Bienaime buys $10,270 in shares - Investing.com
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS - MarketBeat
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS - marketbeat.com
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research - marketbeat.com
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com - Investing.com India
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
KROS Q2 2026 Earnings: Wider-than-Expected Net Loss Pressures SharesFull Year Guidance - dars.gov.et
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - Eastern Progress
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock - MarketBeat
Keros (KROS) Today: Moves 4.95% Down to $10.55 in the Latest Session; Market Levels: $10.02 and $11.08 Define the Nearby Reference Levels in the Available RecordPut Support - vinanet.vn
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale - Stock Titan
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - marketbeat.com
Keros Therapeutics (KROS) Drops 5.25% to $10.1 — Support at $9.59 in FocusEarnings Miss Risk - vinanet.vn
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
BofA Securities Maintains Keros Therapeutics(KROS.US) With Hold Rating, Cuts Target Price to $17 - Moomoo
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeat
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):